Abingworth Llp Has Trimmed By $1.22 Million Its Dicerna (DRNA) Stake; Shorts at HYPERDYNAMICS CORPORATION (HDYN) Lowered By 18.8%

June 26, 2017 - By Winifred Garcia

Abingworth Llp decreased Dicerna (DRNA) stake by 64.28% reported in 2016Q4 SEC filing. Abingworth Llp sold 607,932 shares as Dicerna (DRNA)’s stock rose 12.37%. The Abingworth Llp holds 337,825 shares with $973,000 value, down from 945,757 last quarter. Dicerna now has $71.81M valuation. The stock rose 2.94% or $0.1 reaching $3.33. About 87,857 shares traded or 29.54% up from the average. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 5.22% since June 26, 2016 and is downtrending. It has underperformed by 21.92% the S&P500.

HYPERDYNAMICS CORPORATION (OTCMKTS:HDYN) had a decrease of 18.8% in short interest. HDYN’s SI was 370,700 shares in June as released by FINRA. Its down 18.8% from 456,500 shares previously. With 55,100 avg volume, 7 days are for HYPERDYNAMICS CORPORATION (OTCMKTS:HDYN)’s short sellers to cover HDYN’s short positions. It is 0.00% or $0 reaching $1.65 per share. It is down 0.00% since June 26, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Monday, August 10. The stock has “Neutral” rating by Chardan Capital Markets on Monday, August 15. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has “Buy” rating given on Wednesday, November 11 by Stifel Nicolaus. The firm has “Outperform” rating by Cowen & Co given on Tuesday, September 8. The firm has “Neutral” rating by Chardan Capital Markets given on Thursday, June 30. The rating was maintained by Stifel Nicolaus on Thursday, June 30 with “Buy”. Stifel Nicolaus maintained it with “Buy” rating and $16 target in Tuesday, May 10 report. As per Tuesday, January 31, the company rating was reinitiated by Leerink Swann. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has “Buy” rating given on Monday, December 12 by H.C. Wainwright.

Investors sentiment increased to 1.09 in Q4 2016. Its up 0.53, from 0.56 in 2016Q3. It is positive, as 10 investors sold DRNA shares while 13 reduced holdings. 10 funds opened positions while 15 raised stakes. 10.74 million shares or 7.45% less from 11.61 million shares in 2016Q3 were reported. Fmr Ltd Co reported 2.76 million shares or 0% of all its holdings. Eventide Asset Mngmt Limited Liability holds 377,000 shares or 0.07% of its portfolio. Creative Planning owns 0% invested in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 5,400 shares. Millennium Management Ltd Liability Corp holds 0% or 39,140 shares. Paloma Prtn Communication invested 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Natl Bank Of America Corporation De owns 1,095 shares. Pdt Prtn Lc holds 0.01% or 29,300 shares. Bankshares Of Ny Mellon Corp stated it has 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Manufacturers Life The reported 671 shares. Blackrock Invest Lc has invested 0% in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Wells Fargo And Communication Mn reported 140 shares. Blackrock Institutional Trust Na, California-based fund reported 80,368 shares. Blackrock Advisors Limited Co holds 2,670 shares or 0% of its portfolio. Tfs Cap Llc owns 27,704 shares for 0.02% of their portfolio. 337,825 were accumulated by Abingworth Limited Liability Partnership.

Hyperdynamics Corporation is an independent gas and oil exploration firm with prospects in offshore Republic of Guinea in Northwest Africa pursuant to rights granted to the Company by Guinea (the Concession) under a Hydrocarbon Production Sharing Contract (PSC). The company has market cap of $36.09 million. The Company’s primary focus is the advancement of exploration work in Guinea. It currently has negative earnings. The Company, through its subsidiary, SCS Corporation Ltd, conducts international gas and oil exploration activities in Guinea.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: